Avior G, Dagan O, Shochat I, et al. - A retrospective single-centre case series with chart review was carried out to investigate the malignancy rate and test performance for Bethesda System for Reporting Thyroid Cytopathology (BSRTC) categories in a middle‐sized institution outside the United States (US). Researchers included a total of 364 patients who had undergone thyroid surgery with a preoperative BSRTC between the years 2010 and 2018 at our institution. All medical records were examined to collect demographics, nodule's size, BSRTC, and final pathology to evaluate the malignancy rate for each BSRTC. The data indicated that the revised 2017 BSRTC management recommendations for thyroid nodules are also valid in the smaller non‐US centre, supporting its use globally, despite variations from the reported 2017 BSRTC malignancy rates.